Empagliflozin Confers Kidney-Protective Benefits After Acute MI
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 9, 2024 -- Empagliflozin confers kidney-protective benefits for patients with acute myocardial infarction (MI) and an increased risk for heart failure, according to a study presented at the European Society of Cardiology Congress 2024, held from Aug. 30 to Sept. 2 in London.
Rahul Aggarwal, M.D., from Harvard Medical School in Boston, and colleagues conducted a multicenter trial involving patients with acute MI and an increased risk for heart failure. A total of 6,522 patients were randomly assigned to empagliflozin or placebo, stratified by baseline estimated glomerular filtration rate (eGFR).
The researchers observed a similar initial decline in eGFR at two weeks from randomization, with an adjusted mean eGFR change from baseline of −4.8 and −3.7 mL/min/1.73 m2 in the empagliflozin and placebo groups, respectively. By 24 months, eGFR was similar to baseline in the empagliflozin group, but had decreased significantly in the placebo group (adjusted mean difference in eGFR change, 4.1 mL/min/1.73 m2), with consistent patterns for baseline eGFR ≥ or <60 mL/min/1.73 m2. With empagliflozin, reductions were seen in total hospitalizations for heart failure, total adverse events of heart failure or all-cause mortality, and total adverse events of heart failure (risk ratios, 0.67, 0.79, and 0.63, respectively), which were consistent across baseline eGFR.
"Our data also showed that empagliflozin was safe to initiate soon after an acute MI, regardless of the patient's baseline kidney function," lead author Deepak L. Bhatt, M.D., M.P.H., from the Mount Sinai Fuster Heart Hospital, said in a statement.
Several authors disclosed ties to biopharmaceutical companies, including Boehringer Ingelheim and Eli Lilly, which manufacture empagliflozin and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Replacing Sedentary Activity With Sleep, Exercise Beneficial in Acute Coronary Syndrome
TUESDAY, May 27, 2025 -- For patients evaluated for acute coronary syndrome, replacing sedentary behavior with sleep, light-intensity physical activity, or moderate- to...
Early Combination of Lipid-Lowering Therapy Beneficial After Myocardial Infarction
MONDAY, April 28, 2025 -- For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial, according to a study published online in...
ACC: Cannabis Use Linked to Increased Risk for MI in People Aged 50 Years and Younger
TUESDAY, March 18, 2025 -- Cannabis use is associated with an increased risk for adverse cardiovascular events, including myocardial infarction (MI), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.